PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 5, 2026Cancer Research0 citations

Abstract 3449: Heterogeneity in outcomes of cytokine blockade identifies plausible role for SPP1+macrophages in colorectal liver metastasis immune suppression

View Full Paper
KGKristin E. GoodsellJCJ. W. S. CarterSDSheela Damle

Key Points

  • The aim is to examine the role of SPP1+ macrophages in colorectal cancer liver metastases and their effect on immunotherapy outcomes.
  • Classified cases as responders or non-responders to IL-10 blockade.
  • Performed bulk and single cell RNA sequencing, and multiplexed immunofluorescence on treated samples.
  • Analyzed apoptosis rates using clinical data and statistical methods.
  • IL-10 blockade increased apoptosis from 29% to 45%, indicating a significant response.
  • Non-responders had a higher expression of genes related to T cell activation and cytotoxicity.
  • SPP1 expression was associated with non-responders, showing more OPN/SPP1+ cells compared to responders.

Abstract

Abstract The failure of immunotherapy to demonstrate a benefit in patients with colorectal cancer liver metastases (CRLM) is likely due to both liver-specific immune tolerance and cancer-specific immune evasion mediated by tumor associated macrophages (TAMs), suppressive cytokines (e.g., interleukin-10/IL-10), and immune checkpoints, such as PD-1-PD-L1. We previously demonstrated that IL-10 blockade can activate antitumor immunity in tumor slice cultures (TSC) of CRLM, while PD-1 blockade failed to do so. We hypothesized that immunosuppressive TAMs in the tumor immune microenvironment (TIME) contributed to treatement failure.Cases were classified as responders or non-responders to IL-10 blockade. Clinical characteristics were analyzed. Bulk and single cell RNA sequencing (RNAseq) and multiplexed immunofluorescence (mIF) were performed on subsets of treated samples. RNAseq data were analyzed in R (Seurat) and Python (Scanpy). AIVIA software was used to quantify SPP1 staining on mIF.IL-10 blockade increased apoptosis (29% to 45%, p0.05) across all TSC (n=59). Using two tailed t-test, cases were classified by percent apoptosis in anti-IL-10 treatment versus control as responders (53% vs 23%, p0.05) and non-responders (25% vs 24%, p=0.67).Clinical characteristics including primary site, metachronous/synchronous metastasis, mutation status, and prior therapy were not significantly different between groups. BulkRNAseq demonstrated no difference in baseline IL-10 or IL-10 receptor gene expression between groups. scRNAseq identified TAMs as the major source and both T cells and TAMs as recipients of IL-10 signaling.While non-responders had higher baseline expression of genes related to CD8+ T cell activation (p=0.03) and cytotoxicity (p=0.03), they also had a higher abundance of M2-macrophage related genes (p=0.02) and CD8+ T cell exhaustion (p=0.04). Further interrogation of immunosuppressive signaling pathways showed that SPP1 (encoding osteopontin/OPN) is largely expressed by TAMs within CRLM, while T cells and TAMs express OPN receptors (CD44, ITGB1). mIF demonstrates colocalization of macrophage markers (CD68/CD163) and OPN/SPP1. Preliminary analysis showed that non-responders had significantly more OPN/SPP1+ cells on baseline mIF (4.3 vs 0.1%, P=0.01).Importantly, we determined that OPN secretion is significantly reduced in responders but unchanged in non-responders. The results suggest a role for TAM-related OPN-mediated immunosuppression in the failure of immunomodulatory treatment.We identify SPP1+ TAMs as a potentially critical immunosuppressive population in the TIME of liver metastases. Future work will leverage both orthotopic CRLM models and spatial transcriptomics of human tumors to explore the role of osteopontin signaling in CRLM. Citation Format: Kristin Goodsell, Jason Carter, Sheela Damle, Xiuyun Jiang, Heidi Kenerson, Ian N. Crispe, Venu G. Pillarisetty. Heterogeneity in outcomes of cytokine blockade identifies plausible role for SPP1+macrophages in colorectal liver metastasis immune suppression abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 3449.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Goodsell et al. (2026) studied this question.

synapsesocial.com/papers/69d1fca7a79560c99a0a24c4https://doi.org/10.1158/1538-7445.am2026-3449
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Targeting SPP1 + TAMs associated with liver metastasis reverses immunosuppression and synergizes with immunotherapy in colorectal cancer2026 · 4 citations
  2. 2SPP1 high macrophage-induced T-cell stress promotes colon cancer liver metastasis through SPP1/CD44/PI3K/AKT signaling2025 · 18 citations
  3. 3Potential crosstalk between SPP1 + TAMs and CD8 + exhausted T cells promotes an immunosuppressive environment in gastric metastatic cancer2024 · 79 citations
  4. 4Abstract C025: Effect of Chemotherapy on Spatial Relationships in the Colorectal Cancer Immune Microenvironment2026
  5. 5Single-cell transcriptomic analyses provide insights into SPP1+ TAM-mediated immune suppression and CD8+ T cell dysfunction in lung cancer2025 · 16 citations